肿瘤免疫治疗相关PD-(L)1 PET靶向核素探针应用研究进展  

Progress in the application of PD-(L)1 PET-targeted nuclide probes for tumor immunotherapy-related studies

作　　者：蒙茜 孙洪福 黄伟 Meng Xi;Sun Hongfu;Huang Wei(Department of Radiation Oncology,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China)

机构地区：[1]山东省肿瘤防治研究院(山东省肿瘤医院)放疗科、山东第一医科大学(山东省医学科学院),济南250117

出　　处：《中华放射医学与防护杂志》2024年第2期158-162,共5页Chinese Journal of Radiological Medicine and Protection

摘　　要：免疫治疗已经进入多种肿瘤的临床治疗。程序性细胞死亡分子-1/配体-1(PD-1/PD-L1)免疫检查点的阻断治疗是目前最重要的肿瘤免疫治疗方法。目前临床上通过免疫组织化学方法(IHC)检测肿瘤患者PD-L1表达情况并筛选适应证,但PD-L1表达异质性、动态变化性以及样本取材受限等因素限制了经此法对肿瘤患者体内PD-L1表达情况的评估价值。PD-(L)1 PET成像利用放射性标记分子在空间和时间上非侵入性地评估PD-(L)1的表达,和免疫组织化学互补使用,理论上存在不可比拟的优势。本文就PD-(L)1探针分子成像原理、临床研究及存在问题等最新进展做一综述。Immunotherapy has entered the clinical treatment for various tumors,among which the blockade therapy of PD-1/PD-L1 immune checkpoint is currently the most important tumor immunotherapy method.At present,immunohistochemical method are used in clinical practice to detect PD-L1 expression in tumor patients and screen for indications.However,this method is constrained by factors such as heterogeneity,dynamic changes in PD-L1 expression,and limited sample collection.PD-(L)1 PET imaging utilizes radiolabeled molecules to non-invasively assess PD-(L)1 expression in space and time,and complementary use with IHC has theoretically incomparable advantages.This article reviews the latest progress in the PD-(L)1 probe molecular imaging principles,clinical research and existing problems.

关 键 词：程序性细胞死亡分子-1/配体-1 分子成像 正电子发射型计算机断层显像示踪剂 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]